Literature DB >> 28756395

The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap.

Ross L Cameron1, Kimberley Kavanagh2, D Cameron Watt1, Chris Robertson1,2,3, Kate Cuschieri4, Syed Ahmed1, Kevin G Pollock1.   

Abstract

BACKGROUND: Cervical cancer disproportionately affects women from lower socioeconomic backgrounds. A human papillomavirus (HPV) vaccination programme was introduced in Scotland in 2008 with uptake being lower and inequitable in a catch-up cohort run for the first three years of the programme compared with the routine programme. The socioeconomic differences in vaccine uptake have the potential to further increase the inequality gap in regards to cervical disease.
METHODS: Vaccination status was linked to demographic, cytological and colposcopic data, which are routinely collected by the Scottish HPV surveillance system. Incidence rates and relative risk of cervical intraepithelial neoplasia (CIN) 1, 2 and 3 in unvaccinated and vaccinated women were stratified by birth year and deprivation status using Poisson regression.
RESULTS: Women who received three doses of HPV vaccine have significantly decreased risk of CIN 1, 2 and 3. Vaccine effectiveness was greater in those women from the most deprived backgrounds against CIN 2 and 3 lesions. Compared with the most deprived, unvaccinated women, the relative risk of CIN 3 in fully vaccinated women in the same deprivation group was 0.29 (95% CI 0.2 to 0.43) compared with 0.62 (95% CI 0.4 to 0.97) in vaccinated women in the least-deprived group.
CONCLUSIONS: The HPV vaccine is associated with significant reductions in both low-grade and high-grade CIN for all deprivation categories. However, the effect on high-grade disease was most profound in the most-deprived women. These data are welcoming and allay the concern that inequalities in cervical cancer may persist or increase following the introduction of the vaccine in Scotland. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  cancer: cervix; health inequalities; sexually trans dis; social inequalities; vaccination

Mesh:

Substances:

Year:  2017        PMID: 28756395     DOI: 10.1136/jech-2017-209113

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  8 in total

1.  Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.

Authors:  Nancy M McClung; Julia W Gargano; Nancy M Bennett; Linda M Niccolai; Nasreen Abdullah; Marie R Griffin; Ina U Park; Angela A Cleveland; Troy D Querec; Elizabeth R Unger; Lauri E Markowitz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-02-21       Impact factor: 4.254

2.  Changes in human papillomavirus genotypes associated with cervical intraepithelial neoplasia grade 2 lesions in a cohort of young women (2013-2016).

Authors:  Carrie R Innes; Peter H Sykes; Dianne Harker; Jonathan A Williman; Rachael A Van der Griend; Martin Whitehead; Merilyn Hibma; Beverley A Lawton; Peter Fitzgerald; Narena M Dudley; Simone Petrich; Jim Faherty; Cecile Bergzoll; Lois Eva; Lynn Sadler; Bryony J Simcock
Journal:  Papillomavirus Res       Date:  2018-11-01

3.  Impact of HPV vaccination on outcome of cervical cytology screening in Denmark-A register-based cohort study.

Authors:  Lise Holst Thamsborg; George Napolitano; Lise Grupe Larsen; Elsebeth Lynge
Journal:  Int J Cancer       Date:  2018-10-01       Impact factor: 7.396

4.  Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection.

Authors:  Ana Gradissimo; Viswanathan Shankar; Fanua Wiek; Lauren St Peter; Yevgeniy Studentsov; Anne Nucci-Sack; Angela Diaz; Sarah Pickering; Nicolas F Schlecht; Robert D Burk
Journal:  Viruses       Date:  2021-08-05       Impact factor: 5.048

5.  The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot.

Authors:  Francesca Pesola; Christopher Mathews; Matejka Rebolj; David Mesher; Kate Soldan; Henry Kitchener
Journal:  Br J Cancer       Date:  2022-03-26       Impact factor: 9.075

6.  Monitoring HPV vaccine impact on cervical disease: Status and future directions for the era of cervical cancer elimination.

Authors:  Carlos R Oliveira; Linda M Niccolai
Journal:  Prev Med       Date:  2021-03-04       Impact factor: 4.018

7.  Assessing Impact of HPV Vaccination on Cervical Cancer Incidence among Women Aged 15-29 Years in the United States, 1999-2017: An Ecologic Study.

Authors:  Jacqueline M Mix; Elizabeth A Van Dyne; Mona Saraiya; Benjamin D Hallowell; Cheryll C Thomas
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-10-20       Impact factor: 4.090

8.  Substantial Decline in Prevalence of Vaccine-Type and Nonvaccine-Type Human Papillomavirus (HPV) in Vaccinated and Unvaccinated Girls 5 Years After Implementing HPV Vaccine in Norway.

Authors:  Berit Feiring; Ida Laake; Irene Kraus Christiansen; Mona Hansen; Jeanette Stålcrantz; Ole Herman Ambur; Per Magnus; Christine Monceyron Jonassen; Lill Trogstad
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 5.226

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.